BNP-32 (human) hydrochloride

CAS: 124584-08-3

Ref. 3D-FB110257

Información del producto

• Nombre: BNP-32 (human) hydrochloride
• Sinónimos: Brain Natriuretic Peptide-32 (human)H-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-L eu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-OH hydrochloride salt (Disulfide bond)NesiritideBNP (1-32), human, Natriureticfactor-32 (human brain clone lhBNP57), 1,2-Dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane,cyclic peptide deriv., 1: PN:US6028055 SEQID: 1 claimed protein, 6: PN:US20090011997 SEQID: 4 claimed protein, 83: PN: US20080153747 SEQID: 83 claimedprotein, Human brain natriuretic factor-32, Human brain natriuretic peptide-32, L-Histidine,L-seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-arginyl-L-lysyl-L-methionyl-L-a-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-,cyclic (10?, 26)-Disulfide, Natriureticpeptide type-B, Nesiritide, BNP-32 (human)

Descripción

BNP-32 is a peptide hormone that regulates the volume of blood in the heart and lungs. It is used to diagnose congestive heart failure, and also as a treatment for decompensated congestive heart failure. When given as an intravenous infusion, BNP-32 reduces the levels of natriuretic peptides in the blood stream by increasing their breakdown in the kidneys. The disulfide bond between cysteine residues (Cys-Cys) is essential for its activity. BNP-32 has been shown to be effective against infectious diseases such as HIV, hepatitis C, and tuberculosis. It is also used in combination with other drugs to treat high blood pressure. This drug can be administered orally or intravenously and is biocompatible with human tissue because it is chemically stable and non-toxic at therapeutic doses.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 3,464.04 g/mol
• Fórmula: C₁₄₃H₂₄₄N₅₀O₄₂S₄
• Pureza: Min. 95%